Levi & Korsinsky notifies investors that it has commenced an investigation into Zai Lab Limited (NASDAQ: ZLAB) concerning potential violations of the federal securities laws.
Zai Lab issued a press release on September 3, 2025, announcing that "the final analysis of the Phase 3 FORTITUDE-101 trial evaluating bemarituzumab in combination with chemotherapy (mFOLFOX6) in first-line gastric cancer has been completed." While the interim analysis of the trial revealed a significant improvement in overall survival when compared to chemotherapy alone, the final analysis showed that the previously noted survival advantage had diminished. Zai Lab stated that "[b]ased on the updated results of the FORTITUDE-101 trial, Zai Lab intends to await the results of FORTITUDE-102, evaluating bemarituzumab in combination with nivolumab and chemotherapy in the same patient population, prior to regulatory filing. Data readout from FORTITUDE-102 is anticipated by the end of 2025 or the first half of 2026." Following this news, Zai Lab's American Depositary Receipt ("ADR") price fell over 6% on September 3, 2025.
If you suffered a loss on your Zai Lab Limited securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure





